Project Grant R01CA295576
Award Date 8/12/25
Completion Date 7/31/30
Dollars Obligated $630K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- This $781,436 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by Cold Spring Harbor Laboratory to optimize anti-NMDAR (N-methyl-D-aspartate receptor) antibodies for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen for anti-NMDAR antibodies that can effectively target NMDAR-positive TNBC cells while...
- The National Cancer Institute awarded a $1,634,811 Project Grant to Natsar Pharmaceuticals, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports the drug development of RK-33, a small molecule inhibitor of the DDX3 RNA helicase, for the treatment of triple-negative breast cancers (TNBCs). TNBCs constitute 10-25% of all breast cancers and primarily affect younger women and African-American women, with limited treatment options. Preclinical studies...
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $616,071 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). The project, which runs from February 2025 to January 2030, involves a partnership between UTHSCSA and Riverwalk Therapeutics, Inc., a spin-off company incorporated by UTHSCSA....
- This $403,485 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of novel platinum-based therapeutics that can effectively induce high levels of reactive oxygen species (ROS) to treat triple-negative breast cancer (TNBC). The research, conducted by The Methodist Hospital Research Institute in Texas, aims to create new drug candidates that can rapidly eradicate TNBC cells and suppress tumor growth, particularly in cases...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- The Leland Stanford Junior University (Stanford University) has been awarded a $462,860 Project Grant from the National Cancer Institute (NCI), an institute of the U.S. Department of Health and Human Services, under the NCI's Cancer Treatment Research program (CFDA 93.395). This 5-year grant supports the development of novel targeted radionuclide therapy (TRT) approaches for the treatment of triple-negative breast cancer (TNBC). The key objectives of this project are to develop MUC1-targeted...
- This Project Grant award of $2,840,768 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the therapeutic efficacy and minimize side effects of the chemotherapy drugs cyclophosphamide (CPA) and doxorubicin (DOX) in treating triple-negative breast cancer (TNBC). The key objectives are to improve the metabolic activation of CPA and mitigate the cardiotoxicity of DOX by leveraging dual activation of the human constitutive androstane receptor (HCAR) and...
- This $658,561 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel class of MDM2 degraders for improved treatment of triple-negative breast cancer (TNBC). The lead compound, CH175, has shown promising anti-tumor activity in TNBC patient-derived xenograft models. The key objectives are to: 1) Optimize the CH175 scaffold to increase binding to the MDM2 ring domain and improve anti-TNBC potency, and 2)...